Compulsive Sexual Behaviour Disorder
Clinical research in compulsive sexual behaviour disorder centers on pharmacological approaches aimed at reducing symptom severity, with interest in selective serotonin reuptake inhibitors, opioid receptor antagonists, and combination treatment strategies.
- Escitalopram
- Paroxetine
- Naltrexone
- Combination pharmacotherapy
The sponsor’s work in this area reflects a focus on psychiatric symptom control and the evaluation of treatment options for a behavior-related disorder with limited established therapeutic pathways.
Systemic Sclerosis
Research in systemic sclerosis is directed toward comparing targeted therapies for a complex autoimmune connective tissue disease, with attention to vascular, inflammatory, and fibrotic disease mechanisms.
- Dapagliflozin
- Tocilizumab
- Autoimmune fibrosis
- Inflammatory disease management
The therapeutic interest extends to treatment selection in patients with multisystem involvement, including domains relevant to internal medicine, rheumatology, and immune-mediated tissue remodeling.
Psychiatry and Behavioral Medicine
The sponsor is active in psychiatry through studies of symptom-focused drug treatment for disorders affecting behavior, impulse control, and mental health.
- Behavioral symptom reduction
- Psychopharmacology
- Impulse control
This area highlights interest in clinical management of difficult-to-treat psychiatric conditions using established and repurposed medicines.
Rheumatology and Immunology
Within rheumatology and immunology, the sponsor’s research addresses chronic systemic disease with emphasis on immune modulation and long-term disease control.
- Connective tissue disease
- Immune-mediated inflammation
- Fibrotic complications
These interests align with therapeutic evaluation in conditions where inflammation and fibrosis drive clinical burden and treatment complexity.
